Long-term survival in a smoking caucasian male patient treated with gefitinib for spinal cord compression secondary to lung cancer

Onkologie

Volumn 34, Issue 6, 2011, Pages 326-328

  Longo, Federico ^a   Riquelme, Alejandro ^a   Rodríguez, Mercedes ^a   Olmedo, María E ^a   Garrido, Pilar ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

EGFR; Epidermal growth factor receptor; Gefitinib; Non small cell lung cancer; NSCLC; Second primary tumour; Survival

Indexed keywords

CISPLATIN; DOCETAXEL; GEFITINIB; GEMCITABINE; PEMETREXED;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CASE REPORT; CAUCASIAN; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESIS; SMOKING; SPINAL CORD COMPRESSION; SPINE METASTASIS; SURVIVAL TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES; SMOKING; SPINAL CORD COMPRESSION; SURVIVORS; TREATMENT OUTCOME;

EID: 79957972798     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000328788     Document Type: Article

References (18)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics. CA Cancer J Clin 2010;60:277-300
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346:92-8 (Pubitemid 34438899)
3. Coate LE, John T, Tsao MS, Shepherd FA: Molecular predictive and prognostic markers in nonsmall cell lung cancer. Lancet Oncol 2009;10:1001-10
4. Nakatomi K, Soda H, Kitazaki T, Nakano H, Uchida K, Urabe S, Nakamura Y, Hayashi T, Tsukamoto K, Kohno S: Long-term survival in three patients with metastatic non-small cell lung cancer treated with gefitinib. Lung Cancer 2006; 52:253-5
5. Miyazaki K, Ano T, Nakazawa K, Satoh H, Ohtsuka M: Late fatal recurrence in gefitinibtreated NSCLC patients. Tuberk Toraks 2007; 55:400-3 (Pubitemid 350221686)
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabrbara P, Seymour L: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. N Engl J Med 2005;353:123-32
7. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer. J Clin Oncol 2008; 26:3543-51
8. Cole JS, Patchell RA: Metastatic epidural spinal cord compression. Lancet Neurol 2008;7:459-66 (Pubitemid 351508481)
9. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY: Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-18
10. Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, Liao ML, Bischoff H, Reck M, Sellers MV, Watkins CL, Speake G, Armour AA, Kim ES: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010;28:744-52
11. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57
12. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Snchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67
13. Kalyankrishna S, Grandis JR: Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006;24:2666-72 (Pubitemid 46622088)
14. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase III randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-8
15. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-54 (Pubitemid 46211507)
16. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27
17. Duchateau CS, Stokkel MP: Second primary tumors involving non-small cell lung cancer. Prevalence and its influence on survival. Chest 2005; 127:1152-8 (Pubitemid 46224275)
18. Parsons A, Daley A, Begh R, Aveyard P: Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010;340:b5569